Difference between revisions of "WSI21-23-Case-2"
From MGH Learn Pathology
(Automatic edit to upgrade to new templates) |
(Updating subject, access, and performer) |
||
| Line 17: | Line 17: | ||
Metastatic kinase fusion-related thyroid carcinoma (0.6 cm, in aggregate). | Metastatic kinase fusion-related thyroid carcinoma (0.6 cm, in aggregate). | ||
|reasonCode=Not provided. | |reasonCode=Not provided. | ||
| − | |subject= | + | |subject=MGH |
| − | |performer= | + | |performer=PMS36 |
|authoredOn=February 11, 2021 03:17:13 PM | |authoredOn=February 11, 2021 03:17:13 PM | ||
|requester=Aja51 | |requester=Aja51 | ||
|sequence=2 | |sequence=2 | ||
| + | |access=public | ||
}} | }} | ||
{{Media | {{Media | ||
Revision as of 15:01, June 21, 2022
